Download PDF
Thromb Haemost 2021; 121(07): 891-899
DOI: 10.1055/s-0040-1722353
Coagulation and Fibrinolysis

Effect of the First Factor VIII Infusions on Immunological Biomarkers in Previously Untreated Patients with Hemophilia A from the HEMFIL Study

Larissa Maira Moura de Oliveira‡   *
1   Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
,
Letícia Lemos Jardim‡   *
1   Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
2   Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands
,
Marcio Antônio Portugal Santana
3   Serviço de Pesquisa, Fundação Hemominas, Belo Horizonte, Minas Gerais, Brazil
,
Mônica Hermida Cerqueira
4   Instituto de Hematologia Arthur de Siqueira Cavalcanti (HEMORIO), Rio de Janeiro, Brazil
,
Claudia Santos Lorenzato
5   Centro de Hematologia e Hemoterapia do Paraná (HEMEPAR), Curitiba, Brazil
,
Vivian Karla Brognoli Franco
6   Centro de Hematologia e Hemoterapia de Santa Catarina (HEMOSC), Florianópolis, Brazil
,
Luciana Werneck Zuccherato
1   Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
7   Instituto Mário Penna, Belo Horizonte, Minas Gerais, Brazil
,
Suely Meireles Rezende
1   Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
,
Daniel Gonçalves Chaves
3   Serviço de Pesquisa, Fundação Hemominas, Belo Horizonte, Minas Gerais, Brazil
› Author Affiliations Funding This study was funded by FAPEMIG (CDS – APQ-04185–10 and CDS – PPM-00205–14), CAPES (grant number 88881.068041/2014–01), and CNPq (grant number 456080/2014–7).
› Further Information
    Permissions and Reprints

Abstract

Hemophilia A (HA) is an inherited bleeding disorder which requires continuous replacement with factor (F) VIII concentrate. The main complication of HA is the development of neutralizing alloantibodies which inhibit FVIII activity (inhibitors). The objective of this study was to investigate the effect of the first FVIII infusions on immunological biomarkers in previously untreated patients with HA. Plasma samples were collected at enrollment before any FVIII infusion (T0) and at inhibitor development (INB +/T1) or up to 35 exposure days without inhibitors (INB −/T1). Anti-FVIII antibodies (immunoglobulin M, immunoglobulin G [IgG] 1, IgG3, and IgG4), chemokines (CCL2, CCL5, CXCL8, CXCL9, and CXCL10), and cytokines (interleukin [IL]-2, IL-4, IL-6, IL-10, interferon-γ, tumor necrosis factor, and IL-17) were assessed. A total of 71 children with severe HA were included, of whom 28 (39.4%) developed inhibitors. Plasma levels of anti-FVIII IgG4, IL-6, and CXCL8 were higher at INB +/T1 when compared with INB −/T1. This group presented a mixed cytokine profile and higher plasma levels of CXCL9 and CXL10 when compared with INB +/T1. We conclude that exposure to FVIII triggers a proinflammatory response mediated by IL-6 and CXCL8 in patients with HA who developed inhibitors. Regardless of inhibitor status, the immune system of all HA patients is stimulated after infusions of FVIII.

Keywords

hemophilia A - factor VIII - inhibitors - immune response - immunological biomarkers

Authors' Contributions

L.M.M.O. and L.L.J. performed the research, analyzed the data, and wrote the manuscript; M.P.S., M.H.C., C.S.L., and V.K.B.F. selected the patients and collected the clinical data; L.W.Z. performed the molecular tests; D.G.C. and S.M.R. designed the research, contributed to data analysis, and wrote the manuscript. All authors revised and approved the final version of the manuscript.


* These authors contributed equally to the work.




Publication History

Received: 19 August 2020

Accepted: 21 November 2020

Article published online:
10 January 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Rizza CR, Spooner RJ. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: report on behalf of the directors of haemophilia centres in the United Kingdom. Br Med J (Clin Res Ed) 1983; 286 (6369): 929-933
    CrossrefPubMedGoogle Scholar
  • 2 Mahlangu J, Cerquiera M, Srivastava A. Emerging therapies for haemophilia - global perspective. Haemophilia 2018; 24 (Suppl. 06) 15-21
    CrossrefPubMedGoogle Scholar
  • 3 Peters R, Harris T. Advances and innovations in haemophilia treatment. Nat Rev Drug Discov 2018; 17 (07) 493-508
    CrossrefPubMedGoogle Scholar
  • 4 Hu G, Guo D, Key NS, Conti-Fine BM. Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients. Thromb Haemost 2007; 97 (05) 788-794
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Chaves DG, Velloso-Rodrigues C, Oliveira CA, Teixeira-Carvalho A, Santoro MM, Martins-Filho OA. A shift towards a T cell cytokine deficiency along with an anti-inflammatory/regulatory microenvironment may enable the synthesis of anti-FVIII inhibitors in haemophilia A patients. Clin Exp Immunol 2010; 162 (03) 425-437
    CrossrefPubMedGoogle Scholar
  • 6 Oliveira CA, Velloso-Rodrigues C, Machado FC. et al. Cytokine profile and FVIII inhibitors development in haemophilia A. Haemophilia 2013; 19 (03) e139-e142
    CrossrefPubMedGoogle Scholar
  • 7 Jardim LL, Chaves DG, Silveira-Cassette ACO. et al. Immune status of patients with haemophilia A before exposure to factor VIII: first results from the HEMFIL study. Br J Haematol 2017; 178 (06) 971-978
    CrossrefPubMedGoogle Scholar
  • 8 Verbruggen B, van Heerde W, Novákovà I, Lillicrap D, Giles A. A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen Modification of the Bethesda factor VIII:C inhibitor assay. Thromb Haemost 2002; 88 (02) 362-364
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Rossetti LC, Radic CP, Larripa IB, De Brasi CD. Developing a new generation of tests for genotyping hemophilia-causative rearrangements involving int22h and int1h hotspots in the factor VIII gene. J Thromb Haemost 2008; 6 (05) 830-836
    CrossrefPubMedGoogle Scholar
  • 10 Pio SF, Mühle C, De Oliveira GC, Rezende SM. Detection of int1h-related inversion of the factor VIII gene. Haemophilia 2011; 17 (02) 313-314
    CrossrefPubMedGoogle Scholar
  • 11 Rosendaal FR, Palla R, Garagiola I, Mannucci PM, Peyvandi F. SIPPET Study Group. Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. Blood 2017; 130 (15) 1757-1759
    CrossrefPubMedGoogle Scholar
  • 12 Taylor R. Interpretation of the correlation coefficient: a basic review. J Diagn Med Sonogr 1990; 1: 35-39
    CrossrefPubMedGoogle Scholar
  • 13 Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 2014; 6 (10) a016295
    Google Scholar
  • 14 Lin E, Calvano SE, Lowry SF. Inflammatory cytokines and cell response in surgery. Surgery 2000; 127 (02) 117-126
    CrossrefPubMedGoogle Scholar
  • 15 Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354 (06) 610-621
    CrossrefPubMedGoogle Scholar
  • 16 Delignat S, Rayes J, Russick J, Kaveri SV, Lacroix-Desmazes S. ABIRISK consortium. Inhibitor formation in congenital hemophilia A: an immunological perspective. Semin Thromb Hemost 2018; 44 (06) 517-530
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K. Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol 1994; 56 (05) 559-564
    CrossrefPubMedGoogle Scholar
  • 18 Luster AD. Chemokines--chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338 (07) 436-445
    CrossrefPubMedGoogle Scholar
  • 19 Ragni MV, Wu W, Liang X, Hsieh CC, Cortese-Hassett A, Lu L. Factor VIII-pulsed dendritic cells reduce anti-factor VIII antibody formation in the hemophilia A mouse model. Exp Hematol 2009; 37 (06) 744-754
    CrossrefPubMedGoogle Scholar
  • 20 Gaitonde P, Peng A, Straubinger RM, Bankert RB, Balu-Iyer SV. Downregulation of CD40 signal and induction of TGF-β by phosphatidylinositol mediates reduction in immunogenicity against recombinant human Factor VIII. J Pharm Sci 2012; 101 (01) 48-55
    CrossrefPubMedGoogle Scholar
  • 21 Sun J, Yuan Z, Abajas YL. et al. A retrospective study of the cytokine profile changes in mice with FVIII inhibitor development after adeno-associated virus–mediated gene therapy in a hemophilia A mouse model. Hum Gene Ther 2018; 29 (03) 381-389
    CrossrefPubMedGoogle Scholar
  • 22 Qadura M, Waters B, Burnett E. et al. Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice. Haemophilia 2011; 17 (02) 288-295
    CrossrefPubMedGoogle Scholar
  • 23 van Helden PMW, van den Berg HM, Gouw SC. et al. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A. Br J Haematol 2008; 142 (04) 644-652
    CrossrefPubMedGoogle Scholar
  • 24 Boylan B, Rice AS, Dunn AL. et al; Hemophilia Inhibitor Research Study Investigators, Hemophilia Inhibitor Research Study Investigators. Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay. J Thromb Haemost 2015; 13 (01) 47-53
    CrossrefPubMedGoogle Scholar
  • 25 Montalvão SAL, Tucunduva AC, Siqueira LH, Sambo AL, Medina SS, Ozelo MC. A longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titre inhibitor in haemophilia A patients. Haemophilia 2015; 21 (05) 686-692
    CrossrefPubMedGoogle Scholar
  • 26 Whelan SFJ, Hofbauer CJ, Horling FM. et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood 2013; 121 (06) 1039-1048
    CrossrefPubMedGoogle Scholar
  • 27 Lazarchick J, Hoyer LW. The properties of immune complexes formed by human antibodies to factor VIII. J Clin Invest 1977; 60 (05) 1070-1079
    CrossrefPubMedGoogle Scholar
  • 28 Hartholt RB, Wroblewska A, Herczenik E. et al. Enhanced uptake of blood coagulation factor VIII containing immune complexes by antigen presenting cells. J Thromb Haemost 2017; 15 (02) 329-340
    CrossrefPubMedGoogle Scholar
  • 29 Varthaman A, Lacroix-Desmazes S. Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?. Haematologica 2019; 104 (02) 236-244
    CrossrefPubMedGoogle Scholar